Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies - (Tables)

v3.19.1
Significant Accounting Policies - (Tables)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Disaggregation of Revenue
The following table presents net revenues disaggregated by type:

 
 
Year Ended December 31,
 
 
2018
 
2017
Prescribed dietary supplements
 
$
7,678,003

 
$
1,092,271

Prescription drugs
 
10,192,742

 
818,132

Sales force revenue
 
456,056

 
278,165

License and other revenue
 

 
25,000,000

Grant revenue
 

 
624,569

Total revenues, net
 
$
18,326,801

 
$27,813,137